Purpose

The purpose of this study is to learn if there is a difference in recovery time when using sugammadex versus neostigmine. The researchers also hope to add further knowledge and data to the safety of using sugammadex in burn patients who are hypermetabolic.

Condition

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Undergoing burn surgery under general anesthesia

Exclusion Criteria

  • Patients without a non-burned upper extremity
  • Renal insufficiency or failure
  • Sensitivity or hypersensitivity reaction to sugammadex
  • Liver impairment, neuromuscular degenerative disease or dependence on drugs or alcohol

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Sugammadex
Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
  • Drug: Sugammadex
    Sugammadex is indicated for the reversal of neuromuscular blockade.
Active Comparator
Neostigmine
Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
  • Drug: Neostigmine
    Neostigmine is indicated for the reversal of neuromuscular blockade.
  • Drug: Glycopyrrolate
    Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.

Recruiting Locations

University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Ashley McCowen
913-588-7419
amccowen@kumc.edu

More Details

Status
Recruiting
Sponsor
University of Kansas Medical Center

Study Contact

Angie Ballew, DC, MS
(913) 945-7420
aballew@kumc.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.